Skip to main content

Table 2 Analgesic outcomes

From: Intrauterine lidocaine and naproxen for analgesia during intrauterine device insertion: randomized controlled trial

Characteristic Lidocaine/Naproxen Lidocaine/Placebo Saline/Naproxen Saline/Placebo P
Physician pain assessment 0.77 ± 0.11 0.56 ± 0.09 0.48 ± 0.11 0.59 ± 0.8 0.238
Visual analog pain score 3.38 ± 2.49 2.87 ± 2.13 3.09 ± 2.18 3.62 ± 2.45 0.456
Post procedure analgesia      0.568
 Yes 10 (25) 8 (20) 9 (22.5) 12 (30.8)  
 No 28 (70) 28 (70) 31 (77.5) 22 (56.4)  
Satisfaction with procedure 4.36 ± 0.84 4.26 ± 0.94 4.3 ± 0.94 4.4 ± 0.9 0.910
Satisfaction with IUD (Day 30)      0.701
 Levonorgestrel 52 mg 4.40 ± 0.75 4.36 ± 0.97 4.35 ± 1.1 4.38 ± 0.89  
 Copper T380A 4.31 ± 0.95 4.16 ± 0.92 4.3 ± 0.81 4.47 ± 0.94  
Physician pain assessment      0.31
 Levonorgestrel 52 mg 0.90 ± 0.72 0.50 ± 0.11 0.55 ± 0.18 0.53 ± 0.12  
 Copper T380A 0.63 ± 0.13 0.63 ± 0.14 0.40 ± 0.11 0.63 ± 0.11  
Visual analog pain score
 Levonorgestrel 52 mg 3.55 ± 0.55 2.45 ± 0.44 2.85 ± 0.45 3.26 ± 0.54 0.09
 Copper T380A 3.26 ± 0.59 3.32 ± 0.52 3.35 ± 0.52 4.00 ± 0.58  
Post procedure analgesia
 Levonorgestrel 52 mg      0.65
 Yes 3 (16) [0.33] 3 (17) [0.23] 5 (25) [0.09] 5 (31) [0.64]  
 No 16 (84) [0.09] 15 (83) [0.06] 15 (75) [0.02] 11 (69) [0.18]  
 Copper T380A      0.43
 Yes 7 (41) [0.45] 5 (28) [0.10] 4 (20) [0.89] 7 (41) [0.45]  
 No 10 (59) [0.21] 13 (72) [0.05] 16 (80) [0.42] 10 (59) [0.21]  
  1. Data are mean ± standard deviation, n%, [X2] unless otherwise specified